CSF1R and benign prostatic hyperplasia: Furthermore, pharmacological blockade of this pathway with sunitinib suppressed fibroblast-induced epithelial proliferation in vitro and reduced prostate enlargement in an androgen-induced BPH mouse model, supporting the potential of CSF1R-targeted strategies for BPH treatment.